Osmol Therapeutics, Inc.
Monday, June 03, 2024
Oncology
Company Presentation Theater 4
Osmol is a clinical stage company developing technology licensed from Yale University for a first-in-class preventative treatment for chemotherapy induced peripheral neuropathy (CIPN) caused by microtubule-based chemotherapy agents, including taxanes, the leading breast cancer chemotherapy treatment. With no approved treatments patients’ only option to prevent CIPN is to reduce the dose or length of chemotherapy treatment, potentially effecting outcomes. The Company’s initial focus is breast cancer patients where up to 80% of patients treated with taxanes develop CIPN.
Our product, OSM-0205, a preventative treatment administered 30 minutes prior to each chemotherapy infusion to protect neurons, has the potential to not only help patients avoid the debilitating effects of CIPN, but improve cancer treatment outcomes for the 50% of patients that have their dose modified. Our mission is to allow patients to maintain their quality of life while receiving the best possible cancer treatment.
Company Website:
http://www.osmoltherapeutics.com
Lead Product in Development:
OSM-0205 a first-in-class preventative treatement for chemotherapy induced peripheral neuropathy (CIPN) and chemotherapy induced cognitive Impairment (CICI) resulting from the off target effects of microtubule based chemotherapies. OSM-0205 potent NCS1 stabilizer discovered by Dr. Barbara Ehrlich, Professor of Pharmacology at Yale School of Medicine. Calcium homeostasis is critical to the homeostasis of cellular function. NCS1 is a highly sensitive calcium sensor protein that maintains resting calcium concentrations and dynamically enhances responses to cell stimuli. Microtubule-based chemotherapy agents destroy tumor cells by disrupting microtubules. These agents also bind to NCS1 leading to a calcium dysregulation that causes neuronal atrophy subsequently resulting in CIPN and CICI. OSM-0205 modulates NCS1 function preventing the chemotherapy induced calcium dysregulation and thereby averting CIPN and CICI , while not impacting the chemotherapy’s microtubule effect on tumor cells.
OSM-0205 is a patented intravenous formulation of an FDA-approved oral CNS medication following the 505 (b)(2) regulatory pathway. The product is currently designed to be administered to patients 30 minutes prior to the chemotherapy infusion to protect neurons from off target effects of the chemotherapy.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Company HQ City
New Haven
Company HQ State
CT
Company HQ Country
United States
CEO/Top Company Official
Bob Linke
Development Phase of Primary Product
Phase I
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())